Pharmacokinetics and pharmacodynamics of antifungals

被引：82

作者：

Andes, David

机构：

[1] Univ Wisconsin, Dept Med, Infect Dis Sect, Madison, WI 53792 USA

[2] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53792 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2006年 / 20卷 / 03期

关键词：

D O I：

10.1016/j.idc.2006.06.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Application of pharmacodynamic principles to antifungal drug therapy of Candida and Aspergillus infections has provided an understanding of the relationship between drug dosing and treatment efficacy. Observations of the pharmacodynamics of triazoles and amphotericin B have correlated with the results of clinical trials and have proven useful for validation of in vitro susceptibility breakpoints. Although there remain many unanswered questions regarding antifungal pharmacodynamics, available data suggest usefulness in the application of pharmacodynamics to antifungal clinical development. Future application of these principles should aid in the design of optimal combination antifungal therapies.

引用

收藏

页码：679 / +

页数：21

相关论文

共 88 条

[1] Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazol [J].

Alexander, BD ;

Schell, WA ;

Miller, JL ;

Long, GD ;

Perfect, JR .

TRANSPLANTATION, 2005, 80 (06) :868-871

[2] Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo:: Fluconazole and Candida albicans [J].

Andes, D. ;

ForreSt, A. ;

Lepak, A. ;

Nett, J. ;

Marchillo, K. ;

Lincoln, L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2374-2383

[3] Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models [J].

Andes, D ;

Safdar, N ;

Marchillo, K ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :674-684

[4] In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Lowther, J ;

Bryskier, A ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1187-1192

[5] Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].

Andes, D ;

van Ogtrop, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120

[6] In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model [J].

Andes, D ;

van Ogtrop, M .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :938-942

[7] In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3165-3169

[8] In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model [J].

Andes, D ;

Marchillo, K ;

Stamstad, T ;

Conklin, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1193-1199

[9] Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis [J].

Andes, D ;

Marchillo, K ;

Conklin, R ;

Krishna, G ;

Ezzet, F ;

Cacciapuoti, A ;

Loebenberg, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :137-142

[10] In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis [J].

Andes, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1179-1186

← 1 2 3 4 5 6 7 8 9 →